Holidayers Revive Hepatitis A Vaccine Market

London, England -- (SBWIRE) -- 06/20/2012 -- Tourists represent the biggest at-risk group for contracting hepatitis A, according to new findings released by pharmaceuticals intelligence provider GlobalData.

The new report* indicates that, to combat this, vaccinations are expected to become more common in correlation with an increase in global travel, which is introducing individuals to geographic areas with a higher risk of HAV infection.

Market growth for HAV vaccines has been only moderate in recent years due to a lack of awareness or symptoms, and the fact that vaccination is not mandatory in most countries. However, following cases such as the epidemic of HAV in Puglia, southern Italy, in 1998, the use of hepatitis A preventive vaccines rose dramatically among adolescents and toddlers.

Future increases in vaccination coverage for hepatitis A will rely on awareness programs about viral hepatitis by bodies such as Sistema Epidemiologico Integrato dell'Epatite Virale Acuta (SEIEVA) in Europe, and the Centers for Disease Control and Prevention (CDC) in the US.

The available vaccines for HAV are already very successful, boasting a high efficacy of almost 90% and displaying a high safety profile, with less than 1% of patients suffering serious adverse events. As a result, little scope is left to tempt new drug entrants in the near future and no novel vaccines are expected to emerge in the near future. However, opportunity lies in the development of an oral hepatitis A vaccine which could be available in single doses, as currently many people fail to take their additional second "booster" vaccine.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Hepatitis-A-Vaccine-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare&CompanyID=sbwirereportstore

HAV is an acute infectious disease of the liver, transmitted person-to-person by the ingestion of contaminated food or water, or through direct contact with an infectious person. Hepatitus is often asymptomatic in young children, but adults often suffer symptoms including fatigue, fever, nauseau, and abdominal pain. Exposure to HAV does not cause chronic infection or liver disease, but very rare cases of acute liver failure have resulted from HAV infections.

GlobalData's analysis shows that the global hepatitis A preventive vaccines market stood at $874.8m in 2006 and grew at a compound annual growth rate (CAGR) of 7.3% to reach $1,245.4m in 2011. GlobalData forecasts that the global hepatitis A preventive vaccines market will grow at a CAGR of 4.8%over the next eight years to reach $1,805.8m by 2019, helped along by awareness campaigns boosting the vaccine market in developed economies.

This report is an essential source of information and analysis on the global hepatitis A preventive vaccines market. It identifies the key trends shaping and driving the global hepatitis A preventive vaccines market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis A preventive vaccines market sector.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

GlobalData is an industry analysis specialist company providing business information products and services. Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Hepatitis-A-Vaccine-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cost of Solar Energy Generation to Compete with Traditional Sources as US and China Reach Grid Parity by 2017

London, England -- (SBWIRE) -- 06/20/2012 -- The cost of energy generation from clean sources such as solar power is edging ever-closer to those attributed to traditional sources, fostering growth in the renewable energy sector, according to a new report by energy experts GlobalData.

The new report* shows that the global cumulative installed solar PV capacity increase of 100% demonstrated during 2009-2011 is likely to grow even further as mass power consumers China and the US reach grid parity within the next few years.

In the US, solar PV technology is expected to reach grid parity for some PV projects in 2014, and by 2017 most regions in the country are expected to reach grid parity in alignment with average electricity prices in the residential sector. China is also due to witness similar developments, with grid parity for solar expected to reach in most regions by 2015-2016.

Levelized cost of electricity (LCOE) is the price at which electricity must be generated from a specific source to account for the cost of the energy-generating system. The LCOE for solar PV will continue to decrease due to declining capital costs and increasing capacity factor. These factors, combined with a lack of fuel costs, low operations and maintenance costs mean that the LCOE of solar PV technology is expected to be lower than average retail electricity prices from 2017 onwards.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?CompanyID=jpr&ID=Grid-Parity-for-Wind-and-Solar-Power-Future-Outlook-and-Impact-Analysis&ReportType=Industry_Report&title=Alternative_Energy&CompanyID=sbwirereportstore

Solar PV is a major renewable source of energy across the globe, accounting for around 14% of the global renewable capacity. It is also the fastest growing renewable power source in the world, having grown at a compound annual growth rate (CAGR) of 56.4% over the past five years. The global solar PV market witnessed high growth in 2010 and 2011, with 44.3 gigawatts (GW) of installed capacity coming online in these two years, in contrast to the 14.8 GW installed during 2008 and 2009.

Europe is currently the largest market for solar PV, but is expected to lose its market share to newly emerging markets such as India and China. These countries have announced ambitious PV targets, and are seen as the next hotbeds for PV investment, cushioned by favorable policy frameworks for the development of the renewable energy market. The global solar PV installed capacity will continue to grow at a CAGR of 20.2% 2011-2020, to reach 362,842 MW by 2020.

This report provides historical and forecast (2006-2020) installed capacity for global wind and solar PV market, and analyzes Levelized Cost of Energy (LCOE) for wind and solar PV in major countries such as the US, Germany, Italy, the UK, China and India. LCOE for solar PV and wind is compared with conventional fuel sources such as coal, Combined Cycle Gas Turbine (CCGT) and nuclear power, and the report also provides analysis on solar PV grid parity and its future outlook for the abovementioned countries.

The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's Team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Grid-Parity-for-Wind-and-Solar-Power-Future-Outlook-and-Impact-Analysis&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Integrated Oil Companies Evolve to Ensure Future Profits

London, England -- (SBWIRE) -- 06/20/2012 -- Integrated Oil Companies (IOCs) are turning towards more challenging opportunitites for oil production, such as onshore unconventional reserves and conventional resources in deepsea areas, according to research conducted by oil and gas experts GlobalData.

The new report* shows that several integrated oil companies (IOCs) decided to restructure business segments in 2011, directing their focus on upstream activities for the next five years. This follows a steady decrease in oil and gas discoveries since 2010 and a global depletion of conventional reserves, which has made the use of advanced technologies to drill in deep sea regions far more appealing.

A large number of deepsea reserves have been successfully detected, increasing the need for high capital expenditure in the upstream sector. IOCs are being prompted to increase capital expenditure in their upstream businesses to enable expansion of their E&P activities in conventional as well as unconventional resources.

GlobalData analysis indicates that increased capital expenditure is required for IOCs to remain competitive with their pure-play E&P counterparts. Reserve Replacement Ratios (RRRs) represent the amount of new reserves found in comparison to the amount of oil produced over a set amount of time.

The RRR helps in deciding the future prospects of a company and the number of years it will be able to sustain its current production levels with its current reserves. IOCs have, on average, seen relatively lower RRRs than those of upstream pure-play companies during the period 2007-2011, suggesting that pure-play companies have been more competitive in increasing new reserves, and further highlighting the need for IOCs to step up their focus on upstream activities in order to survive competition in the future.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Business-Restructuring-in-International-Oil-Companies-%28IOCs%29-Increasing-Focus-on-Upstream-Business-With-Spin-Offs-and-Divestitures-in-Downstream-Operations&ReportType=Industry_Report&title=Oil_~_Gas&CompanyID=sbwirereportstore

Many IOCs have also restructured their downstream operations, due to the various environmental regulations on refining units utilized in certain developed countries. Refining capacities are now only expected to be added in markets with looser environmental regulations, and a considerable decline in planned refinery construction and capacity expansions in North America and Europe is being countered by huge refining capacity expansions planned for Asia-Pacific, the Middle East, Africa, and South and Central America.

This report provides information about the key divestments in the downstream sector undertaken by integrated companies in order to raise the capital needed to focus on upstream activities. Information about divestments of downstream assets and plans for growth in the upstream sector by major integrated oil companies also features in the report.

This report was built using data and information sourced from company reports, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Business-Restructuring-in-International-Oil-Companies-%28IOCs%29-Increasing-Focus-on-Upstream-Business-With-Spin-Offs-and-Divestitures-in-Downstream-Operations&ReportType=Industry_Report&title=Oil_~_Gas&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Evolving MRSA Infections Will Face New Foes Thanks to Drug Development

London, England -- (SBWIRE) -- 06/20/2012 -- It is hoped that an increase in serious hospital-acquired infections such as MRSA will be combatted by the new and improved drug treatment options in the pipeline due for launch in the near future, according to pharmaceutical experts GlobalData.

The new report has found that cases of Methicillin-resistant Staphylococcus aureus (MRSA) have been on the increase during the past decade, due to the steady growth of the elderly and immunocompromised population, and the emergence of multi-drug-resistant (MDR) bacterial strains.

MRSA is a common bacterial, hospital-acquired infection which occurs in patients with weakened immune systems, and is resistant to beta-lactam antibiotics such as methicillin, amoxicillin, penicillin and oxacillin. MRSA can cause a broad variety of infections, ranging from superficial skin eruptions to life-threatening cellulitis, blood and surgical infections, pneumonia and urinary tract infections.

Stringent hygiene measures in hospitals have led to a decrease in MRSA cases among hospital inpatients, but overall disease prevalence has seen an escalation due to increase in the communityassociated MRSA infections, and MRSA is expected to gain further momentum over the coming years.

According to GlobalData, pharmaceutical companies are attempting to combat this in coming years with a strong therapeutics pipeline, which currently boasts a variety of 84 molecules, including both antibiotics and vaccines, in various phases of development. Research and development (R&D) activity is more prominent in the early stages of pipeline. However, six molecules are in Phase III that would enter in the therapeutics market within the next few years.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Methicillin-Resistant-Staphylococcus-Aureus-MRSA-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare&CompanyID=sbwirereportstore

First-in-class (FIC) molecules account for 40% of the pipeline, while best-in-class (BIC) molecules contribute a 31% share, showing that a new generation of medicines is fast emerging. Phase III BIC molecule Tedizolid Phosphate could be the most promising drugs in development at present, as this second-generation oxazolidinone has shown superior results over current market favourite linezolid.

These drugs would capture the gap in the market caused by the patent expiries of Zyvox (linezolid) in 2015, Cubicin (daptomycin) in 2017 and Tygacil (tigecycline) in 2016. The developments will also help to strengthen the current treatment spectrum in light of public controversies surrounding the serious adverse effects of some treatment offerings. For example, Vibativ (telavancin) has been known to cause damage to the kidneys, while Tygacil increases the mortality risk, which led the Committee for Medicinal Products for Human Use (CHMP) to recommend a restriction in the drug's use. The MRSA therapeutics market therefore offers significant opportunities for stronger upcoming products.

GlobalData analysis shows that the global MRSA therapeutics market stood at $1,448.2m in 2006, which then grew at a compound annual growth rate (CAGR) of 12.9% to reach $2,659.7m in 2011. GlobalData forecasts that the market will grow at a CAGR of 3.4% over the next eight years to reach $3,468m by 2019.

This report is an essential source of information and analysis on the global MRSA therapeutics market. It identifies the key trends shaping and driving the market, and also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MRSA therapeutics market sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Methicillin-Resistant-Staphylococcus-Aureus-MRSA-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New Gout Treatments May Get Toes Tapping

London, UK -- (SBWIRE) -- 06/12/2012 -- Joint pain caused by gout may be on its way out, as the ever-expanding market encourages the discovery of groundbreaking new therapies, according to a new report by healthcare experts GlobalData.

As the new report* explains, pharmaceutical companies are scrambling to expand into the gout market, as it is now the most common form of inflammatory joint disease in men and women aged over 40 years, caused by genetic metabolic defects, kidney impairment, alcohol abuse and even meat-heavy diets. Prevalence has been rising steadily over the last 20 years, due to the increased longevity of the population, alongside dietary changes and increases in obesity.

While the current gout therapeutics market is competitive, due to the availability of a number of treatments, there is a significant unmet need in due to safety concerns and treatment failures.

Currently, acute gout can be treated using NSAIDs, corticosteroids and Colcrys, while doctors can prescribe uricosurics sulphinpyrazone, benzbromarone or xanthine oxidase inhibitors to treat chronic gout. In addition, a drug called Krystexxa can catalyze the oxidation of uric acid to decrease its deposition in the body.

However, scope exists for new drug entrants able to safer and more effective treatments. As the present pipeline for new gout therapeutics is strong, with 12 molecules currently in development, it is hoped that the near future will see the healthcare sector produce these much-anticipated breakthroughs. Notably, two molecules in pre-registration, Ilaris and Rilonacept, are first-in-class (FIC), while Phase III contains best-in-class molecule Lesinurad. Growth over the next decade is anticipated as a result of the planned launch of Rilonacept and Ilaris this year.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?CompanyID=jpr&ID=Gout-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare&CompanyID=sbwirereportstore

Gout is caused by the accumulation of uric acid crystals in the joints and their surrounding tissues, developing over years as the acid builds up, due to the kidney's failure to eliminate it from the body. This can cause acute attacks characterized by sudden and severe episodes of pain, stiffness and inflammation. Chronic gout can develop, causing chronic arthritis and permanent damage to the affected joints and sometimes to the kidneys.

GlobalData's analysis shows that the global gout therapeutics market grew at a compound annual growth rate (CAGR) of 13.4% from $527.4m in 2006 to $988.7m in 2011, and is predicted to grow further at a CAGR of 12.5% to reach $2.5 billion by 2019, providing further incentive for pharmaceutical companies to explore the market in future.

The report is an essential source of information on the global gout therapeutics market, and provides analysis of a number of key areas. It identifies the key trends shaping and driving the global gout disease therapeutics market, and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global gout disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Gout-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe: +44 207 753 4299 / +44 1204 543 533
Asia Pacific: +91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Neuroendocrine Cancer Will Face Tough Fight Against Strong Future Treatment Options

London, England -- (SBWIRE) -- 06/08/2012 -- Exciting clinical developments in the field of neuroendocrine carcinoma mean that patients are likely to receive a host of new treatment options within the next few years, according to a new report by healthcare intelligence company GlobalData.

The new report shows several new drugs are anticipated to be launched in the coming years, along with a multitude of upcoming pipeline drugs, which are expected to revolutionize the currently accepted treatment for the cancer.

The pancreatic neuroendocrine tumors (NET) therapeutics market is currently dominated by two recently approved drugs, Sutent (sunitinib) and Afinitor (everolimus). While these drugs each display high efficacy and are expected to delay disease progression, both are associated with serious side effects. Therefore, safer medications are desperately sought by patients and physicians. GI carcinoid NET patients also have need for more treatment choices, as Sandostatin LAR (octreotide) is the only currently approved drug and individuals are at risk of developing resistance against certain Somatostatin (SST) analogs such as octreotide and lanreotide.

High market growth is anticipated in the future, primarily due to new medications due for launch, including Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0- Tyr3-Octreotate) for gastrointestinal (GI) carcinoid and pancreatic NETs, and pasireotide (SOM 230) and Somatuline (lanreotide acetate) Autogel/Depot for GI carcinoids NETs. GlobalData research indicates that the neuroendocrine carcinoma pipeline is also strong, with 15 molecules in different phases of development. These drugs are expected to change the treatment paradigm, offering lower side effects and bringing with them a strong level of market competition between pharmaceutical companies.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Neuroendocrine-Carcinoma-Therapeutics-Pipeline-Assessment-and-Market-Forecast-to-2019&CompanyID=sbwirereportstore

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019.

This report is an essential source of information and analysis on the global neuroendocrine carcinoma market, which identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Neuroendocrine-Carcinoma-Therapeutics-Pipeline-Assessment-and-Market-Forecast-to-2019&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Lifestyle and Infectious Diseases Encourage In Vitro Diagnostics Market in Emerging Countries

London, England -- (SBWIRE) -- 06/08/2012 -- The emerging countries of Brazil, Russia, India and China (BRIC) represent a promising region for the diagnostic testing industry, as population growth and unhealthy lifestyles mean the patient population is growing rapidly, according to a new report from healthcare experts GlobalData.

The new report predicts that the in vitro diagnostics (IVD) market will be driven by new technological advancements, a shift towards Point of Care (POC) testing and the adoption of cost cutting measures over the coming years. The ever increasing patient pool, improving healthcare infrastructure, and enhanced health awareness and affordability will also keep the IVD market buoyant in BRIC countries.

The increasing prevalence of lifestyle disorders and emergence of infectious diseases are expected to fuel future growth. In 2009, the Chinese government initiated healthcare reforms that invested $123 billion in the construction of hospitals and healthcare centers within rural areas, providing for many underserved citizens and opening new markets for medical device manufacturers. In addition, with the population of India estimated to exceed 1.7 billion by 2050, surpassing China, the underlying demand for healthcare is anticipated to display a strong boom.

The immunochemistry market accounted for 32% of the total revenue generated by the in vitro diagnostics market of emerging countries last year. Immunochemistry rapid tests are in high demand in the emergency departments of hospitals, as their use is imperative in emergency situations where practitioners must be able to obtain faster test results. BRIC countries are facing the double burden of a high incidence of infectious diseases and an increasing burden of non communicable diseases (NCDs) such as cancer and cardiovascular disorders. The increasing incidence of these diseases in BRIC countries provides opportunity for growth in the immunochemistry industry to cater to increased demand for testing for tumor markers and cardiac markers.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=In-Vitro-Diagnostics-IVD-Emerging-Countries-Brazil-Russia-India-China-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

The market for In Vitro Diagnostics (IVD) in the BRIC countries is expected to grow at a compound annual growth rate (CAGR) of 16% to reach a revenue of $11.7 billion in 2018. China is the largest in vitro diagnostics market among emerging countries, with a 56% contribution valuing $2.2 billion in 2011; this is expected to reach $7.1 billion by 2018. Brazil was the second largest in vitro diagnostics market among the emerging countries in 2011, valued at $946.1m. During the same year, the Indian in vitro diagnostics market was worth $581.4m, and the Russian in vitro diagnostics market was valued at $267.4m.

This report provides key data, information and analysis on the In Vitro Diagnostics (IVD) market in emerging countries. It provides market landscape, competitive landscape and market trends information on the IVD market in emerging countries. The report also provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics, while reviewing the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=In-Vitro-Diagnostics-IVD-Emerging-Countries-Brazil-Russia-India-China-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Rising Healthcare Spend and Cosmetic Surgery in Emerging Economies Boosts Sutures Market

London, England -- (SBWIRE) -- 06/07/2012 -- Increasing healthcare expenditure in emerging economies, including on aesthetic procedures, is having a positive effect on the expansion of the surgical sutures market, according to a new report by medical intelligence company GlobalData.

The new report states that a rising interest in cosmetic procedures, combined with technological advancements, the growing demand for outpatient surgeries and increasing healthcare expenditure due to older, more wealthy populations, in emerging countries such as China, India and Brazil will support market growth for medical equipment such as surgical sutures.

Emerging economies such as India and China are expected to drive the demand for operating equipment in the future, where the markets for surgical sutures are forecast to grow at a respective compound annual growth rate (CAGR) of 4.3% and 4.7%, to reach market values of $115.5m and $274.8m in 2018. The Brazilian surgical sutures market is also predicted to grow at a slightly lower CAGR of 3.8%, to reach $220.1m in 2018.

The strong economic growth forecast in these emerging economies is expected to lead to increased investments in healthcare infrastructure, due to increasing patient affordability, the availability and demand for healthcare insurance, and general improvements in healthcare services offered. China and India are the most populous countries in the world, and are therefore anticipated to provide significant growth opportunities for manufacturers for years to come.

http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Bariatric-Surgery-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&ReportType=Industry_Report&CompanyID=sbwirereportstore

While the number of people opting for plastic surgery is increasing on a global scale, including in emerging economies, the highest concentration of surgeries still take place in the US. According to statistics released by the American Society for Aesthetic Plastic Surgery (ASAPS) in April 2011, the demand for plastic surgery procedures increased by 9% between 2009 and 2010 alone, and has grown by a total 155% since 1997. Around 9.5 million plastic surgery procedures were performed in the US in 2010, during which year $6.6 billion was spent by US citizens on cosmetic surgery procedures, meaning it will be some years yet before emerging economies reach the kind of levels demonstrated by the US.

The global market for surgical sutures is forecast to reach a market value of $4,233m by 2018, growing at a CAGR of 4.4% during 2011-2018.

The report provides market landscape, competitive landscape and market trends information on the surgical sutures market and provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For Sample Pages, please click or add the below link to your browser:

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Surgical-Sutures-Global-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore
Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Growth of Offshore Wind Market Spins Out to Related Markets

London, England -- (SBWIRE) -- 05/25/2012 -- The global wind energy market witnessed huge growth during 2010-2011, as total wind power capacity around the world grew by 20.6%, according to a new report by energy intelligence provider GlobalData.

The new report* suggests that the growth of major wind power markets in the US, Germany, Spain, India, Italy and France is expected to slow down during the coming years, but emerging markets within Asia- Pacific and South and Central America are expected to easily fill this void.

In the near future, the offshore wind power market is expected to boom, with mega wind power projects due to become operational. Offshore wind power development is mainly concentrated in Europe, which accounts for over 3.2 gigawatts (GW) of offshore wind power capacity. While offshore wind power only accounts for 1.5% of the total wind market at the moment, with large scale commercial offshore wind farms currently in the planning and construction phases, capacity is expected to reach 52.1 GW in 2020, representing 7.1% of the total market.

Related markets are also benefitting from the growing popularity of offshore wind power. For example, offshore wind turbine installation vessel revenue increased from an estimated $21.4m in 2006 to $161.2m in 2010, and is predicted to reach $2,156.5m by 2020. Vessels are crucial for the installation of large offshore wind foundations and turbines. Around 12 new second generation vessels are expected to be in European seas in 2012 and 2013 to cater to the growing offshore wind power installations.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Vessels-Cables-and-Foundations-in-the-Offshore-Wind-market-Global-Market-Size-Cost-Analysis-Market-Share-and-Demad-Supply-Scenario-to-2020&CompanyID=sbwirereportstore

Similarly, the global export cable market grew from an estimated 42km in 2006 to 225.1km in 2011, and is expected to grow to 648.2km in 2020 due to the increasing number of wind farms and their increasing distance from shore. The offshore wind turbine foundation market is also expected to grow with offshore wind market and is expected to reach $6,528.8m in 2020.

Global wind energy installed capacity increased from 74,212.1 megawatts (MW) in 2006 to 238,351.0 MW in 2011, of which 40,714.0 MW came online in 2011. Against a backdrop of increasing investment from emerging economies, global wind power installed capacity will reach 736,956.7 MW by 2020.

This report provides an understanding of the global offshore wind market, including historical and forecast installed capacity and market share by offshore wind farm developers and turbine manufacturers. It also provides information of the various vessels used in the installation of turbines and foundation, the supplydemand scenario, vessel operator revenues, cost of vessels, a breakeven analysis of vessels, and the competitive landscape for the vessel operators in the offshore wind market.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Vessels-Cables-and-Foundations-in-the-Offshore-Wind-market-Global-Market-Size-Cost-Analysis-Market-Share-and-Demad-Supply-Scenario-to-2020&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Investor Interest Returns to Canada’s Montney Shale

London, England -- (SBWIRE) -- 05/17/2012 -- Canada's Montney shale play is gaining huge attention due to its unconventional gas reserves, securing enormous investments as operators compete for valuable areas, a new report by business intelligence expert GlobalData has found.

The new report* found that decreasing conventional resources in North America, coupled with an increasing focus on the development of unconventional resources, has been increasing production in the region for the last few years, with the Montney shale currently attracting the majority of unconventional development in Canada.

Historically, this play was largely overlooked by operators, due to low natural gas prices and low levels of reserves in the play. However, the Montney shale play is now expected to attract increasing numbers of investments due to drilling activities occuring as result of a reduction in royalty rates by the government of Alberta.

Unconventional resources in Canada are attracting different mergers, acquisitions and asset transactions deals to the country, due to the efforts of oil and gas operators to strengthen their reserves and production portfolios. One of the major asset transactions in the Montney shale was PETRONAS's acquisition of around 50% working interest in Progress Energy Resources for approximately $1,103.8m in 2011.

Over 25 major operators currently operate in the area, and strong developmental growth in the shale has rewarded leading producers such as EnCana with high-quality natural gas.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Montney-Shale-in-Canada-2011-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&CompanyID=sbwirereportstore

Natural gas production in the Montney shale play began in 2006, with 46 drilling permits issued, leading to production of approximately 6.94 billion cubic feet (bcf) of natural gas. Production increased throughout 2006-2010 at an average annual growth rate (AAGR) of 61.3% to reach 80.4bcf, from a total of 159 wells. Between January and October 2011, the Montney shale produced a record 98.3bcf of natural gas.

This report analyzes the recent activities in the Montney shale play by detailing the operational activities in the play, analyzing drilling and operational activities, production rates and well decline curves. It provides information on production trends in the Montney shale play with forecasts to 2020, while analyzing the competitive landscape of the Montney shale by detailing operations of the top five companies. The report also highlights infrastructure details in the shale play and details merger and acquisition activities during the period 2007-2011 inclusive.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Montney-Shale-in-Canada-2011-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Nuclear Reactors Across the Globe Getting New Lease of Life, With US Leading the Way

London, England -- (SBWIRE) -- 05/17/2012 -- The US is leading the way in nuclear plant life extension and upgrades, according to a new report by energy intelligence company GlobalData.

The new report* suggests that the growing demand for electricity, increasing safety margins and attempts to avoid the costs associated with new builds are driving the way in which power plants are maintained.

Plant Life Extension (PLEX) and Plant Life Management (PLIM) are vital issues for ensuring the extended operational life for Nuclear Power Plants (NPPs). PLEX is a process in which the original design life of the NPP is extended, and many countries, including the US, Canada and France, are adopting plant life extension as an economical method to meet the growing need for electricity and avoid investment in the construction of new installations. PLIM, on the other hand, helps to optimize a plant's operating life and maximize its value, managing the life of a plant in a safe and economic way.

The growing global demand for power is one of the main contributing factors for the increasing importance of PLEX. During 2000 to 2010, electricity consumption grew at a Compound Annual Growth Rate (CAGR) of 3.5%, from 13,044,433 gigawatt hours (GWh) to 18,454,883 GWh. Consumption for 2012 to 2020 is expected to grow at a CAGR of 4%, increasing from 20,114,049 GWh to 27,496,560 GWh.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Plant-Life-Extension-%28PLEX%29-and-Plant-Life-Management-%28PLIM%29-for-Nuclear-Reactors-Global-Landscape-Analysis-to-2020&CompanyID=sbwirereportstore

To operate safely beyond their original design life, NPPs must undergo maintenance, engineering updates and refurbishment, but the capital cost for building new nuclear plants is still considerably higher than extending their operational life. In turn, the capital cost of plant life management for a long-term operation is lower in comparison to investment in replacement capacity. However, some additional investment in plant modifications, such as power upgrading and safety improvements, may be needed.

North America is the largest market for PLEX, valued at $42,698m, with the US holding a majority market value of $33,656m. The Nuclear Regulatory Commission (NRC) in the US has approved license renewals for around 71 reactors, with 15 currently under review and a further 17 more license applications expected in the forecast period.

In Europe, the major PLEX markets are France, the UK, Russia and the Ukraine, with respective market values of $10,044m, $1,870, $1,784m and $1,728m. Numerous extensions were planned in Europe; however, as a result of the 2011 Fukushima disaster, some countries are now phasing out nuclear power from their energy mix.

This report covers the global plant life extension (PLEX) market, key drivers and restraints of PLEX, PLIM approaches and the Power Uprate market. It gives a detailed study of the PLEX process and provides comprehensive information on the size of the PLEX markets worldwide. Key players and developments in the PLEX market and power uprate market are also covered in the report.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Plant-Life-Extension-%28PLEX%29-and-Plant-Life-Management-%28PLIM%29-for-Nuclear-Reactors-Global-Landscape-Analysis-to-2020&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Need for Speedy Treatment Drives Point-of-Care Testing Success

London, England -- (SBWIRE) -- 05/17/2012 -- Technological advancements in laboratory automation, including point-of-care (POC) testing, and initiatives to increase patient satisfaction are transforming the clinical chemistry market, according to a new report by medical intelligence company GlobalData.

The new report* suggests that rapid growth of POC testing will spread worldwide in the coming years, as a result of rising patient and physician satisfaction, increasing awareness of laboratory testing for disease prevention, and increasing disposable income in emerging economies.

Rapid tests and POC testing have become increasingly popular due to high levels of doctor and patient satisfaction, which has led to market growth. These testing methods cut down on trips to laboratories, waiting time for results, length of hospital stays, and follow-up appointments with physicians to discuss results. They also have a reduced blood sample volume requirement for pediatric cases, which improves upon a routine treatment for a huge market. Studies have shown that, with POC results, physicians are twice as likely to modify or intensify treatments, and are able to minimize delays in treatment that could otherwise result in adverse complications.

The increasing number and complexity of tests, coupled with a shortage in laboratory staff, is leading to a greater level of automation in laboratories. Labor accounts for around 65% of operating expenses in a typical laboratory, and automating a laboratory can expand its capabilities while achieving significant savings.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Clinical-Chemistry-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

Emerging economies such as India and China are expected to drive growth in the clinical chemistry market in the future. Growing health consciousness among middle and high-income families in India is providing significant business opportunities for preventive healthcare, while in China clinical chemistry is being supported by the government and national institutions. The China National Accreditation Committee for Laboratories (CNACL) exists to support clinical laboratory accreditation, and the Ministry of Health is also preparing additional regulations, indicating both an individual and national concern.

The global market for clinical chemistry was valued at $11.1 billion in 2011, and is forecast to grow at a compound annual growth rate (CAGR) of 6.5%, to reach $17.3 billion in 2018. The US is the largest clinical chemistry market, valued at $4.3 billion in 2011 and expected to reach $6.5 billion by 2018, growing at a CAGR of 6.2% during that time period. In contrast, the clinical chemistry markets in China and India were valued at only $703 million and $198 million respectively in 2011, but are forecast to grow at CAGRs of 17.8% and 19.4% to reach $2,210 million and $683 million, respectively, by 2018.

This report provides key data, information and analysis on the global clinical chemistry market. It provides market landscape, competitive landscape and market trends information on the clinical chemistry market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. It also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Clinical-Chemistry-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Caspian Region Countries Argue Access to Reserves in Caspian Sea

London, England -- (SBWIRE) -- 05/17/2012 -- Kazakhstan, Turkmenistan and Azerbaijan are looking to boost their economies and reduce their payments to Russia by gaining access to the fossil fuels present in the Caspian Sea, according to a new report by energy intelligence company GlobalData.

The new report* shows that these countries are seeking to free themselves from Russia's oil and gas pipeline monopoly by gaining access to Iran's cut of lucrative Caspian Sea resources.

The Caspian Sea region is estimated to hold around 12% of all global oil reserves, containing 75 billion barrels of oil and 6.9 trillion cubic meters (tcm) of proven gas reserves. In 1991, after the collapse of the Soviet Union, the region's hydrocarbon resources were distributed among the five littoral states, and have remained in dispute ever since.

The original treaties signed by Iran with the Soviet Union prior to its disintegration state that Kazakhstan, Turkmenistan, Azerbaijan and the Russian Federation are to share half of the Caspian resources, while the remaining 50% belongs to Iran. However, Russia, Azerbaijan and Kazakhstan consider the body of water to be a closed sea and therefore wish to share its resources based on the United Nations (UN) convention of the Law of the Seas, which would see Iran getting a share of only 13%. Iran has instead proposed that all states should be allocated a 20% share or agree to hold joint control over the entire resource.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Oil-and-Gas-Exploration-and-Production-in-the-Caspian-Region-Market-Analysis-Competitive-Landscape-and-Forecast-to-2020&CompanyID=sbwirereportstore

However, this idea is not popular with countries in the Caspian region, who are seeking to develop their infrastructure to diversify export routes. The region's existing regional pipeline infrastructure passes through Russia, and oil and natural gas producers are forced to sell their products at below-market prices to Russia, or pay transit fees to Gazprom for transportation. Turkmenistan experienced a huge decline in its gross domestic product (GDP) in 2009, due to payment disputes with Gazprom, as its economy is highly dependent on the oil and gas industry.

Therefore, several pipeline projects have been planned in the region to expand potential export markets. Shareholders of the Caspian Pipeline Consortium (CPC) pipeline, commissioned in 2001 to run from the Tengiz oil field to the Russian Black Sea port of Novorossiysk, plan to expand its capacity to 1.34 MMbpd by 2013. The Nabucco pipeline, expected to become operational in 2014, will connect Turkey to Austria via Romania, Bulgaria and Hungary, with the capacity to carry 31 billion cubic meters (bcm) of natural gas. This will allow Azerbaijan and Turkmenistan to export their natural gas production to consumers in Europe independently of Russia.

Crude oil and natural gas production from the Caspian Sea region has increased from 8,511.7 million barrels of oil equivalent (MMboe) in 2000 to 12,151.7 MMboe in 2011 at an average annual growth rate (AAGR) of 3.2%, and is predicted to increase to 15,426.2 MMboe in 2020 at an AAGR of 2.7%

This report provides analysis on the oil and gas industry in the Caspian Sea region. It gives information about the region's oil and gas market until 2020, and the key oil and gas projects and key companies in the littoral states of the Caspian Sea region: Azerbaijan, Kazakhstan, Iran, Russia and Turkmenistan. The report also provides the key drivers and challenges for the industry in the current industry environment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Oil-and-Gas-Exploration-and-Production-in-the-Caspian-Region-Market-Analysis-Competitive-Landscape-and-Forecast-to-2020&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Surgery-Seeking Travelers Flock to Emerging Countries for Cosmetic Procedures

London, England -- (SBWIRE) -- 05/17/2012 -- The blooming medical tourism market in BRIC countries (Brazil, Russia, India and China), offering affordable cosmetic surgeries for patients across the world, is leading to increased profits for wound care device companies, according to a new report by medical intelligence company GlobalData.

The new report* predicts that busy operating rooms will drive the wound care management market in BRIC countries, while the availability of high-quality devices at competitive prices has further boosted sales.The number of surgeries conducted in BRIC countries is increasing due to the growing popularity of medical tourism, alongside an increase in the elderly population. This increases the number of devices healthcare centers require, as doctors rely on devices to assist with the closing of incisions and the healing of wounds.

The populations of BRIC countries are ageing rapidly, increasing in the number of elderly people and leading to a heightened need for surgery, and thus a rise in the utilization of wound care devices. By 2030, citizens aged 65 and over are anticipated to exceed 230 million in China and 126 million people in India.

The wound care management devices market in the emerging BRIC countries grew at a compound annual growth rate (CAGR) of 4.5% from $840 million in 2004 to $1.1 billion in 2011, and is expected to grow at a CAGR of 4.7% to reach $1.6 billion by 2018.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Wound-Care-Management-Emerging-Countries-Brazil-Russia-India-China-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

Wound care devices in China alone had an estimated market value of $523 million in 2011, representing the largest wound care management devices market in the BRIC countries, accounting for a 45.7% share. The wound care management devices market in Brazil accounted for 31.9% of the market in BRIC countries in 2010, with a value of $365 million. The Indian and Russian markets were estimated at $171 million and $85 million, respectively, or 14.9% and 7.5% of the market.

This report provides key data, information and analysis on the wound care management market in emerging countries. It shows market landscape, competitive landscape and market trends information on the wound care management market in emerging countries. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. It also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Wound-Care-Management-Emerging-Countries-Brazil-Russia-India-China-Opportunity-Assessment-Competitive-Landscape-and-Market-Forecasts-to-2018&CompanyID=sbwirereportstore

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Botox Sales Increasing as Beauty Fans Seek No-Knife Alternative

London, England -- (SBWIRE) -- 05/07/2012 -- Botox will continue its reign as a bestseller in US beauty clinics due to competitive pricing and reductions in side effects, according to a new report by medical intelligence company GlobalData.

The new report* states that facial aesthetics represent a popular cosmetic treatment, as they offer long-term results at competitive prices without any need for surgical procedures. Botox in particular is predicted to maintain its lead in terms of market share during future years, due to increased patient comfort, short procedure times and immediate results.

Botox can be used to treat chronic wrinkles of the forehead, eyelids, lips and neck, and is the most effective non-surgical anti-wrinkle solution available today, working in just five to 10 minutes. The ingredients used in botox degrade within six months, which means that both the results from treatment, as well as any adverse side effects, are temporary. This acts to lower the risks of treatment and improve the rate of income for practitioners – especially in the US, which accounts for 40% of the botox market. High levels of competition in the future market will result in decreasing price trends in the US, encouraging further popularity.

The dermal fillers market will grow in the future due to the increasing consumer preference for hyaluronic acid-based dermal fillers (HA fillers), which offer fewer side effects in exchange for results lasting just three to six months. This may be good news for aesthetic centers, as HA fillers will provide recurring income.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Facial-Aesthetics-%28Botulinum-Toxin-Dermal-Fillers%29-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&companyID=sbwire

In contrast, the Particle and Polymer Fillers (PPF) market is expected to struggle, as the longevity of aesthetic results lasting up to two years is countered by a higher side effects profile. Collagen products will continue to experience their historic decline in sales, due to increasing awareness of other options such as botox and HA fillers.

Currently, no facial aesthetic procedure can offer permanency, and the longevity of results correlates with higher medical risks. Long-term market growth may depend upon the ability to extend the longevity of results from facial injections, in order compete more strongly against cosmetic surgery. Still, the global botox market is forecast to reach $2.9 billion by 2018 at a CAGR of 14%. The entire global market for facial aesthetics is forecast to reach $4.7 billion in 2018, of which the US is expected to contribute over US$2 billion.

This report provides key data, information and analysis on the global facial aesthetics market. It gives the market landscape, competitive landscape and market trends information for the facial aesthetics market, and provides comprehensive information on the key trends affecting the market, as well as key analytical content. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Facial-Aesthetics-%28Botulinum-Toxin-Dermal-Fillers%29-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Energy Efficient Lamps Shine Light on Environmental Sustainability

London, England -- (SBWIRE) -- 05/04/2012 -- Energy efficient lighting is becoming increasingly important as an immediate solution to rising electricity consumption, with the increasing compatibility of Compact Fluorescent Lamps (CFL) with existing lighting infrastructure spurring sales, according to a new report by business intelligence company GlobalData.

The new report* found that the CFL market will flourish over the next few years, due to a steep rise in the market for new lamps and for replacements.

Lighting appliances consume approximately 19% of total generated electricity. Environmental concerns and government awareness programs drive the CFL market, as the need to decrease emissions has compelled countries to look for clean technologies.

North America consumes the largest amount of electricity for lighting globally, followed by Europe. Many governments of countries within these regions have initiated awareness programs to lower the financial and environmental implications of their energy usage, and energy efficient lighting solutions such as CFLs are addressing these issues.

The need for efficient power consuming technologies has also boosted the sales of CFLs in many developing countries, proving that the technology is attractive at all economic levels. The global market for CFLs is therefore increasing with the adoption of energy efficient lighting.

The phase-out of inefficient lamps drove CFL unit sales throughout 2006-2010, and the continuation of this phase-out until 2014 is expected to support the CFL market in the future.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Compact-Fluorescent-Lamp-%28CFL%29-Market-Global-Market-Size-Price-Analysis-Regulations-and-Key-Countries-Analysis-to-2020&companyID=sbwire

The replacement market is expected to increase its contribution in total CFL sales during the forecast period, due to the growing use of CFLs worldwide. In 2010, the replacement market consisted of around
40% of total CFL sales, but by 2020, much of the world will have already adopted this technology, and so over 85% of sales will stem from the lamp replacement market.

Favorable legislation, rising energy demand, and environmental concerns are major market drivers. However, market growth is still inhibited by a lack of uniform standards, lack of awareness among consumers, hazards in waste disposal, and the expensiveness of CFL products. If these issues are overcome, the growth of the CFL market could soar.

The global CFL market size increased from $6.82 billion in 2006 to $9.44 billion in 2010 at a CAGR of 8.4%. Revenue from CFL sales is expected to increase by about 4% over the next ten years to reach approximately $14 billion by the end of 2020.

This report provides an understanding of the technology, key drivers and challenges in the global CFL market. It provides detail overview on CFL technology, which includes key features and basis of CFL classification, and provides historical (2006-2010) and forecast data to 2020 for CFL unit sales, average price per unit, and market size for global and key countries such as the US, Canada, Brazil, Mexico, Germany, the UK, China and Japan. The research provides a brief overview of major companies such as GE Lighting, LLC, Osram GmbH and Philips Lighting at a global level. Key countries section in the report also covers key regulations supporting the CFL market development and a market index, which compares a country's CFL market based on certain parameters.

The report is built using data and information sourced from primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Compact-Fluorescent-Lamp-%28CFL%29-Market-Global-Market-Size-Price-Analysis-Regulations-and-Key-Countries-Analysis-to-2020&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Mobile Technology to ‘Modernize’ Healthcare Sector as Gadgets Improve Care to Patients With Chronic Conditions

London, England -- (SBWIRE) -- 05/04/2012 -- Is set to take off due to the impetus provided by public and private stakeholders across the healthcare spectrum to modernize and streamline this overburdened sector, according to a new report by business intelligence expert GlobalData.

The new report* shows that the rapid emergence of mHealth technology will revolutionize future healthcare delivery and management by saving lives and reducing the economic burden imposed by growing chronic conditions such as diabetes, obesity and hypertension.

Governments across the world are now implementing public health pilots that use mHealth to promote connected care delivery and management across their network of healthcare sites. Providers see mHealth as a means of improving their productivity, while consumers are keen to adopt these technologies in order to integrate medical treatments with their lifestyle unobtrusively.

Mobile technology has been adapted to enhance healthcare delivery and management throughout the last decade, during which period mobile technology has become essential in all aspects of day-to-day life. The digitalization of medical information for exchange through a connected healthcare infrastructure demonstrates the key changes taking place to attempt to modernize the medical market space.

The emergence of mobile technology in the healthcare arena has also been propelled by the global financial crisis, which resulted in a renewed focus on improving cost efficiency, the improvement of clinical outcomes, and the quality of care provided to patients at home.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Mobile-Health-Devices-and-Applications-Global-Market-Briefing-to-2018&companyID=sbwire

mHealth technologies have the potential to address these key shortcomings in healthcare delivery, while imposing a lower economic burden. They have been shown to improve patient and physician convenience, enable remote monitoring, and improve care-coordination among medical professionals, patients and public health systems. This has proven to be particularly effective in the remote monitoring and management of chronic illnesses, reducing health expenditure while encouraging consumer-centric medical care.

A notable increase in mHealth related product development, market consolidation and the emergence of health-related businesses demonstrates the impact mHealth is having on vendors in the healthcare spectrum. In particular, companies from the telecom and Information Technology (IT) sectors are expected to benefit.

Given these trends, the mHealth market is expected to significantly revolutionize healthcare delivery and management in the future, growing in value from an estimated $0.5 billion in 2010 to over $8 billion by 2018.

GlobalData's new report, "Mobile Health Devices and Applications – Global Market Briefing to 2018" provides key data, information and analysis on the global mobile health devices and applications market. It gives the market landscape, competitive landscape and market trends information for the mobile health devices and applications market, and provides comprehensive information on the key trends affecting the market, as well as key analytical content. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Mobile-Health-Devices-and-Applications-Global-Market-Briefing-to-2018&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Haynesville Shale Continues to Favour Louisiana over East Texas

London, England -- (SBWIRE) -- 05/04/2012 -- Gas production from the US's Haynesville Shale continues to favour the state of Louisiana over East Texas, with the former set to become a major gas producing state while pipeline development in East Texas continues to slow, a new report by business intelligence expert GlobalData has found.

The new report* found that several major gas companies are funding extensive infrastructure developments in Louisiana to allow the transport of produce from the shale to end-user markets. This will dramatically increase revenue from the shale, and will dictate the growing competition for mining permits in the area. However, investment in the same shale in East Texas will take the opposite direction as production slows.

The Haynesville shale has emerged as one of the most promising natural gas producing shales in the US. The total production from Haynesville/Bossier shale increased from 427.23 billion cubic feet equivalent (bcfe) in 2008 to 1,877.15bcfe in 2010, and is estimated to exceed 6,000bcfe by 2015 and 14,000bcfe by 2020.

Production from the Haynesville shale in Louisiana increased significantly from 18.32bcfe in 2008 to 1,198.6.8bcfe in 2010. However, while production from Louisiana has witnessed a rapid increase, production from East Texas has slowed, increasing from 408.91bcfe in 2008 to just 678.59bcfe in 2010.

Drilling activities in the Haynesville shale of Louisiana increased from 1,156 in February 2011 to 1,802 in January 2012, showing a 55% increase in the number of producing wells during the course of less than one year. Chesapeake Energy alone had successfully drilled a total of 708 wells by last October, followed by EXCO with 301 wells, Petrohawk with 262 wells, EnCana with 253 wells, and SWEPI LP with 143 wells.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Haynesville-Shale-in-the-US-2011-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&companyID=sbwire

These companies have also been undertaking activities to increase their production by improving infrastructure and developmental facilities at the Haynesville shale. These companies collaborated with large pipeline companies during 2011, in order to improve transport for the extracted crude gas from producing wells to end-user markets.

Enterprise Products Partners L.P. and Acadian Gas LLC jointly developed the Acadian Haynesville extension pipeline in November 2011, and similarly, Energy Transfer Partners LP completed its (ETC) Tiger Pipeline project in December 2010. This pipeline is connected to seven interstate pipelines, and takes the production from Haynesville/Bossier shale to Midwest and Northeast customers.

The report provides an insight into oil and gas exploration, production and development in the Haynesville shale play. The report also highlights the oil and gas exploration potential of the Haynesville shale play, providing details of the key exploration areas and major exploration companies in the US.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haynesville-Shale-in-the-US-2011-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

US Drug Tests Boost Immunochemistry Diagnostics, but Emerging Countries Due to Make Market Takeover

London, England -- (SBWIRE) -- 05/04/2012 -- China and India are set to dominate the immunochemistry diagnostics market, according to a new report by medical intelligence company GlobalData.

The new report* found that the US presently takes monopoly in the immunochemistry market, largely due to above-average testing for drug abuse. However, emerging countries are anticipated to rise up and account for a proportion of market shares in the near future.

The US currently represents the largest market for immunochemistry devices, accounting for nearly 46% of global revenue in 2011, followed by the European market contributing nearly 29%. Market growth in this sector is being led by an increasing demand for immunochemistry-based diagnostic tests. This is due to the recent launch of several rapid tests, point of care tests based on immunochemistry and companion diagnostics, an increase in the global chronic disease patient population, and market penetration in emerging economies due to the increasing awareness and affordability of these tests. The future looks bright for immunochemistry industry, with intense research and development activity currently being carried out by small and major companies, and over 500 products are in the development pipeline.

Factors driving the US immunochemistry market are high demand for drug abuse and toxicology testing, and the availability of reimbursement for diagnostic tests. Factors such as population aging and high levels of patient awareness build a huge potential home testing market, further boosting the market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Immuno-Chemistry-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&companyID=sbwire

However, GlobalData anticipates that India and China will witness the highest future growth in the immunochemistry market, driven by increasing affordability due to the countries' growing economy, and better awareness among the patient population regarding the benefits of diagnosis. The Chinese immunochemistry market will also benefit from increasing government healthcare expenditures, thanks to the Chinese government announcing a large healthcare reform investment program in 2009 with funding of around $125 billion. Compared to developed nations, emerging economies offer small markets, but have already witnessed the highest growth rates during the past decade.

To take advantage of growing markets in emerging economies, large international companies will have to overcome significant competition from local manufacturers who can offer cheaper products. This is resulting in consolidation between companies in the field, and price wars which may reduce revenue for manufacturers, but will certainly act to foster patient affordability.

The global immunochemistry market is forecast to grow at Compound Annual Growth Rate (CAGR) of 6.8% in the period 2011-2018. The market in India is forecast to grow at a CAGR of 22% over the period 2011-2018, expected to reach a value of $625m, while the Chinese market is forecast to grow at a CAGR of 18% during the same period to gain $2.4 billion in revenues by 2018.

This report provides key data, information and analysis on the global immunochemistry market, providing market landscape, competitive landscape and market trends information on the immunochemistry market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics, while reviewing the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Immuno-Chemistry-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Barnett Shale Pioneers Progress in US Play, Driving Unconventional Oil and Gas Growth in the US

London, England -- (SBWIRE) -- 05/04/2012 -- The major role played by the strategically developed Barnett shale in the US natural oil and gas production is expected to provide a model for the development of other shale plays, according to a new report by GlobalData.

The new report* states that the Barnett shale/Barnett shale combo has historically attracted substantial investments from oil and gas companies. High crude oil prices are anticipated to encourage oil and gas companies to explore and develop Barnett shale combo projects in the future.

Gas wells in the Barnett shale reached a total of 15,731 in March 2012. Drilling and exploration activities have continued to improve, due to advanced fracturing technology that allows oil and gas companies to operate at substantially high recovery rates in the initial production phase. This means that fewer rigs are required in the drilling process to drill a higher number of wells than ever before, improving the productivity of the wells drilled. Operators have also improved their techniques to reduce drilling times, leaving many wells to be drilled from one multi-well pad, which has led to growing efficiency in production rates.

Clearly, these new technologies are paying off for major oil and gas companies, who have been busy acquiring new resources in the liquid-rich area of the Barnett shale play. EV Energy Partners and Enervest have expanded their acreage position in the Barnett shale combo by acquiring natural gas assets worth $1,083m in November 2011. Pioneer Resources has also planned to invest around $170m.

The total number of permits issued in Barnett shale reached 3,642 in 2011. With 1,231 new gas permits issued in 2011 alone, interest is increasing in development and drilling activities in the shale play. It is anticipated that the total number of permits will continue to grow, with more drilling locations popping up not only in this shale play, but in other plays that can mimic its success.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages.aspx?ID=Barnett-Shale-in-the-US-2012-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&companyID=sbwire

During 2003-2011, the cumulative gross gas production of the Barnett Shale was 10.8 trillion cubic feet (tcf). It is expected that future gross production will reach 2,068.6 billion cubic feet equivalent (bcfe) in 2012, later stabilizing at 2,562.5bcfe in 2020.

This report provides insight into the exploration, production, and development of the Barnett gas shale in the US. It highlights the gas exploration potential in the Fort Worth region of the Barnett shale play, providing details of the key exploration areas, major companies exploring the Barnett shale, and the drivers and challenges for shale gas exploration in the US. The report discusses the drilling and exploration activities in different counties of the state of Texas, and also highlights the parameters for gas exploration and production, such as the permits issued in different counties, the companies involved, and the drivers and challenges to development.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Barnett-Shale-in-the-US-2012-Gas-Shale-Market-Analysis-and-Forecasts-to-2020&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cutting-edge technology will dictate the success of vital new deepwater oil reserves, according to a new report by business intelligence company GlobalData.

London, England -- (SBWIRE) -- 04/09/2012 -- The new report* found that Brazil and Malaysia both offer huge resources for future markets, but their challenging terrain demands the use of modern infrastructure, showing a strong need for investment from producing companies.

In 2011, 242 oil and gas discoveries were made globally, with the Asia-Pacific region accounting for a 31.8% share of total discoveries, while a 19.8% share was found in South and Central America. More than half of these discoveries were located in offshore regions, and the recent unearthing of high quality reserves in deep water areas is encouraging an increase in offshore exploration.

The discovery of the Tupi field in 2006 triggered a large number of exploration projects in Brazil, which yielded many positive results. Brazil registered 20 deep water discoveries in 2011, and the country has witnessed the highest number of discoveries in one country since 2008. The majority of these discoveries were made in the sub-salt region of Brazil, which is spread across a vast region of the sea, with large areas remaining unexplored.

In view of the country's impressive fossil fuel findings, oil company Petrobras has declared investment of $224.7 billion for future operations throughout 2011–2015.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Global-Oil-and-Gas-Discoveries-in-2011-Overview-and-Development-Plans-of-Major-Prospects&companyID=sbwire

The Malaysian oil and gas industry also recorded a significant rise in offshore discoveries during 2011. Malaysia is currently one of the least explored countries in the Asia-Pacific region, but, due to decreasing fossil fuel reserves in many South-Asian countries, exploration activities in Malaysia have gained visibility and importance.

In the past six years, all important Malaysian oil discoveries were made in deepwater projects, while further deepwater fields in various regions are expected to be developed by 2015.

However, infrastructure is dictating much of the success of oil extraction efforts in Brazil. While the presence of pipelines and equipment has led the Campos basin to be far more attractive for investors looking to extract oil, infrastructure in the Santos basin is limited, making it difficult to transport extracted oil to the shore.

To combat this, technology is being introduced in the Asia-Pacific region to improve the recovery ratio of reserves. The average recovery ratio in Malaysia is currently 23%, while in other oil-producing countries it reaches around 45%. The introduction of enhanced oil recovery (EOR) will improve the region's technical capabilities, and help to recover more reserves by increasing the recovery ratio.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Global-Oil-and-Gas-Discoveries-in-2011-Overview-and-Development-Plans-of-Major-Prospects&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Financial as well as Non-Financial Incentives will Play a Major Role in Driving the Electric Vehicle (EV) Market in Europe

London, England -- (SBWIRE) -- 04/06/2012 -- Both financial and non-financial incentives are expected to be major drivers of the growth of the EV market in Europe. A number of plans and incentive schemes have been introduced by the governments of different European nations to promote the sale of EVs in the region. Non-financial incentives, such as exclusive parking stations for EV owners, reserved traffic lanes and free use of toll roads, can provide an extra benefits to EV owners by saving their time and money without costing the government to any great degree. This could lead to EVs becoming a financially viable alternative to internal combustion engine (ICE) vehicles in Europe. Therefore, to promote the development of electric vehicles in Europe, it will be important to provide non-financial incentives in the future.

Resource sharing between nations will help in satisfying the electricity needs of different European nations. In order to ensure the optimum utilization of renewable resources, it is important to interlink regional grids, as the potential for generation of electricity from renewable resources for most countries is not significant. For instance, the excess wind energy produced in the UK during periods of low demand for electricity could be transferred to Norway and be used to pump water into the country's hydro electric power stations. Similarly, during periods of high electricity demand in the UK, electricity produced by hydropower in Norway could be transferred to the UK for consumption. The construction of a super smart grid (SSG) in Europe would help in optimizing the utilization of the enormous potential for solar and wind power from North Africa, thereby satisfying the electricity needs of the Mediterranean and the rest of Europe. By developing a unified European power market equipped with smart technologies, the problem related to the high cost of power supply can be easily solved.

The smart grid market in Europe offered a significant opportunity for private funding in comparison to public sector funding in 2011, as government regulations and projects supporting the deployment of smart grid technologies are attracting venture capital firms to invest in smart grid technology in Europe.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Smart-Grid-Landscape-in-Europe-Market-Size-Key-Issues-Regulations-Investment-Analysis-and-Outlook-to-2020&Title=Smart_Grid&ReportType=Industry_Report&companyID=sbwire

The presence of an untapped market in the European smart grid sector is expected to foster the emergence of new technology vendors. However, these new entrants will need significant capital infusions in order to commercialize their technologies. Venture capital firms can act as possible sources of financing to these new businesses, with the aim of generating a better return on their investments once the technology becomes successful commercially.

GlobalData, the industry analysis specialists, have released their latest research "Smart Grid Landscape in Europe - Market Size, Key Issues, Regulations, Investment Analysis and Outlook to 2020", which provides in-depth analysis of smart grid-related developments in Europe. The report covers various aspects of smart grids and related technologies, as well as providing details of market sizing, outlook and competitive landscape analysis. At the outset, the report discusses the investment scenario for smart grids and the related technologies in Europe, taking into consideration the nations actively involved in rolling out smart grid technologies. The report then goes into further detail on the European markets for smart meters, demand response, electric vehicles, distributed generation and energy storage. The report proceeds to explain the smart grid industry's dynamics in Europe, identifying the key market drivers, standards, policies and technology trends, as well as the key development trends in the European Union (EU) and non-EU nations enabling smart grid development in Europe. The report also provides an outlook on the emergence of smart cities, a super smart grid, microgrids and various other technologies in Europe.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Smart-Grid-Landscape-in-Europe-Market-Size-Key-Issues-Regulations-Investment-Analysis-and-Outlook-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Smart_Grid&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Pancreatitis Therapeutics Market is Forecast to Decline until 2019

London, England -- (SBWIRE) -- 04/06/2012 -- GlobalData estimates that the global pancreatitis therapeutics market was worth $36m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 3.6% to $47.7m by 2019. The current treatment options for pancreatitis offer only symptomatic relief and are primarily generic. There are no currently approved disease-modifying drugs in the market and only one in the pipeline (somatostatin). As a result, the market is expected to show slow growth until 2019.

GlobalData has found that the pancreatitis therapeutics market has significant unmet need, implying that the market is moderately served by the current products in terms of efficacy and that there is a good potential for new entrants. Pancreatitis therapies are largely targeted at reducing inflammation, pain and depression, but the current treatment options are limited. They include symptomatic treatment with simple opioid analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), antidepressants and pancreatic enzyme supplements. Non selective NSAIDs and opioids are effective in the early to mid stages of pancreatitis, but often fail to provide adequate chronic pain relief. NSAIDs also cause gastrointestinal complications in a high number of patients.

The current market lacks disease-modifying drugs, resulting in significant unmet need in the treatment of pancreatitis. The only disease-modifying drug in the late stage of the pipeline is somatostatin, which is currently undergoing a university-sponsored trial. This unmet need is expected to persist during the forecast period as patients are forced to depend on symptomatic relief.

The pancreatitis therapeutics market is underserved by the currently marketed drugs. Pancrelipase is the only approved drug for chronic pancreatitis, and although it has shown high levels of safety, the same cannot be said for efficacy. As a result, there is huge potential for new entrants with drugs that can halt or reverse disease progression as well as offering good efficacy and safety profiles in both acute and chronic pancreatitis. There is also huge potential for novel therapies with better symptomatic relief.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx?ID=Pancreatitis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&companyID=sbwire

GlobalData's analysis of the drug development pipeline shows that the late stage pipeline does not offer any immediate hope for pancreatitis patients. It consists of eight First-in-Class (FIC) molecules, but has only one disease-modifying drug, somatostatin, in the late stage of development. The FIC molecules offer distinct advantages over currently used products in terms of disease management. Research for most of them is being carried out by academic institutions and universities. Disease-modifying drugs such as ND- 07, Gala and small molecular glycan inhibitors (G family inhibitors) are in the early stage of clinical development and are not expected to impact the market during the forecast period.

GlobalData, the industry analysis specialist, has released its new report, "Pancreatitis Therapeutics – Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global pancreatitis market. It identifies the key trends shaping and driving the global market and provides insights into the prevalent competitive landscape and the emerging players expected to alter the positioning of the current leaders. Most importantly, the report provides valuable insights into the pipeline products within the global pancreatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Pancreatitis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Chronic Heart Failure Therapeutics Market is Forecast to Show Significant Growth Until 2019

London, England -- (SBWIRE) -- 03/27/2012 -- The global Chronic Heart Failure (CHF) therapeutics market, valued at $3,171.3m in 2006, grew at a Compound Annual Growth Rate (CAGR) of 4.0% to $3,849.9m in 2011. GlobalData's analysis suggests that the global CHF therapeutics market will grow at a CAGR of 3.1% during the forecast period to $4,918.4m by 2019. This growth will be primarily due to the expected launch of LCZ696 in 2015. The treatment-seeking population is expected to grow due to increased life expectancy and awareness of health among patients, as well as growth in the aging population more susceptible to Acute Heart Failure (AHF). Competition in the CHF therapeutics market is weak, as it is dominated by generic drugs such as beta-blockers (metropolol), diuretics (furosemide, spironolactone), digoxin, carvedilol and ramipril. Diovan (valsartan) is the only branded product, but it is expected to lose its patent protection in 2012 in the US.

GlobalData's analysis shows that the current CHF therapeutics market is dominated by generics, which do not treat the underlying cause of the disease. Digoxin, ramipril, carvedilol, metoprolol and Diovan are examples of drugs used to manage the symptoms of CHF, but none have disease-modifying mechanisms.

GlobalData's analysis shows that there are 41 molecules under development for the treatment of CHF. Of these, 78% are First-in-Class (FIC).

There are 10 molecules in Phase III, comprising 25% of the CHF therapeutics pipeline. Of these, 80% are FIC and are being developed for the treatment and management of CHF. LCZ696, a FIC molecule in Phase III, is intended to improve cardiac function in CHF patients. Additionally, lixivaptan, Aranesp (darbepoetin alfa), recombinant human neuregulin-1, Tekturna (aliskiren), and its Fixed Dose Combinations (FDCs) are being investigated to manage early stage CHF patients.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&companyID=sbwire

There are 18 molecules in Phase II, accounting for 45% of the CHF therapeutics pipeline. The majority are being clinically tested for safety and efficacy in improving cardiac function. Phase I of the CHF pipeline accounts for only five molecules, or 12% of the pipeline. The Preclinical Phase contains five molecules, or 12%, and the Discovery Phase comprises three molecules, or 5% of the pipeline.

The pipeline assessment suggests that the CHF therapeutics pipeline is strong, with 30 FIC molecules under development, some of which stand a good chance of becoming the standard first-in-line therapy for the treatment and management of CHF.

Stem cell therapy is capable of significantly improving the CHF treatment pattern. The stem cell therapies in the pipeline will restore cardiac muscle function by regenerating and strengthening the heart muscle cells, potentially improving quality of life for CHF patients

Industry analysis specialist, GlobalData, has released its new report, "Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information on the global CHF therapeutics market, and analyzes a number of key areas. It identifies the key trends shaping and driving the global CHF therapeutics market and provides insights into the current competitive landscape and emerging companies. Most importantly, the report provides valuable insights into the pipeline products within the global CHF sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Global Wound Closure Devices Market is Forecast to Reach $4.6 Billion by 2018

London, England -- (SBWIRE) -- 03/26/2012 -- The global wound closure devices market was valued at $3.3 billion in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $4.6 billion in 2018. The market is expected to be driven by the significant increase in the number of surgeries, especially cosmetic, cardiovascular, orthopedic and laparoscopic surgeries, increase in the number of sports injuries, increase in the global elderly population and large number of road accidents in the emerging countries.

The US wound closure devices market was valued at $1.3 billion in 2011 and is expected to grow at a CAGR of 4.2% to reach $1.7 billion in 2018. The growth will be fuelled by a number of factors such as increase in the number of surgeries especially cosmetic surgeries, increase in elderly population of the country and technological innovations going on in the field of wound closure devices.

According to statistics released by the American Society for Aesthetic Plastic Surgery (ASAPS) in April 2011, the demand for plastic surgery procedures increased by 9% in 2010 and has grown by 155% since
1997. About 9.5 million plastic surgery procedures were performed in the US in 2010 and about 92% or 8.6 million of these procedures were performed on women. Breast augmentation, lipoplasty, abdominoplasty, eyelid surgery and breast reduction procedures were the most sought after procedures in the US in 2010. About $6.6 billion was spent by the Americans on cosmetic surgery procedures in 2010.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Wound-Closure-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&Title=Medical_Devices&ReportType=Industry_Report&companyID=sbwire

In 2011, Covidien plc the leading player in the global wound closure devices market with a share of about 24%. The leadership of Covidien can be attributed to technology innovation, diversified global presence, extensive wound closure devices portfolio and strong financial performance. Covidien continues to invest in new and advanced technologies across all fields, which results in a strong and growing patent portfolio. Through research and development efforts, the company is committed to identifying, receiving and developing new technologies and innovative products. In addition to internal R&D initiatives, through licensing and developing agreements, equity investment and selective acquisition, the company intends to expand its technological capabilities and accelerate the development of new products.

Ethicon and Baxter International are the second and third leading players in the global wound closure devices market with market shares of 14% and 10% respectively.

According to the National Electronic Injury Surveillance System (NEISS), the number of sports injuries in the US increased from about 2.86 million in 2007 to more than 2.91 million in 2009. According to a paper published in the British Journal of Sports Medicine in October 2010, Platelet-Rich Plasma (PRP)

(also known as platelet-rich in growth factors, platelet-rich fibrin matrix, platelet-rich fibrin, fibrin sealant, platelet concentrate) is now being extensively used for the treatment of musculoskeletal injuries in sports. There are many studies which suggest that wound closure devices such fibrin sealants and hemostats can be successfully used in the treatment of sports related injuries.

GlobalData's new report, "Wound Closure Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" provides key data, information and analysis on the global wound closure devices market. The report provides market landscape, competitive landscape and market trends information on the wound closure devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Wound-Closure-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medical_Devices&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm